Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malidi Ahamadi

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Journal of Cardiovascular Pharmacology|January 5, 2022
Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection FractionPo-Wei Chen, Ashit Trivedi, Edward Lee, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 4, 2020
Performance of longitudinal item response theory models in shortened or partial assessmentsLeticia Arrington, Sebastian Ueckert, Malidi Ahamadi, et al.
The AAPS Journal|June 2, 2025
Evaluating the Impact of AI-Based Model-Informed Drug Development (MIDD): A Comparative ReviewBingyu Mao, Yue Gao, Christine Xu, et al.
The AAPS Journal|November 18, 2025
Opportunities for AI-based Model-informed Drug Development: A Comparative Analysis of NONMEM and AI-based Models for Population Pharmacokinetic PredictionBingyu Mao, Yue Gao, Christine Xu, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 24, 2022
Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanomaMalidi Ahamadi, Johannes Kast, Po-Wei Chen, et al.
Journal of Pharmaceutical Sciences|April 21, 2012
Prediction of concentration-time profile and its inter-individual variability following the dermal drug absorptionSebastian Polak, Cyrus Ghobadi, Himanshu Mishra, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 19, 2023
Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migrainePo-Wei Chen, Mats O Karlsson, Sebastian Ueckert, et al.
Medrxiv : the Preprint Server for Health Sciences|March 23, 2026
When Survival Improves But Quality of Life Does Not: A Model-Based Meta-Analysis of Immune Checkpoint InhibitorsYimeng Sun, Shiwon Chang, Kayden Tang, et al.
Journal for Immunotherapy of Cancer|May 19, 2017
Evaluation of dosing strategy for pembrolizumab for oncology indicationsTomoko Freshwater, Anna Kondic, Malidi Ahamadi, et al.
Clinical and Translational Science|June 9, 2022
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy developmentJohannes Kast, Saeideh Nozohouri, Di Zhou, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Journal of Cardiovascular Pharmacology|January 5, 2022
Population Pharmacokinetic Properties of Omecamtiv Mecarbil in Healthy Subjects and Patients With Heart Failure With Reduced Ejection FractionPo-Wei Chen, Ashit Trivedi, Edward Lee, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 4, 2020
Performance of longitudinal item response theory models in shortened or partial assessmentsLeticia Arrington, Sebastian Ueckert, Malidi Ahamadi, et al.
The AAPS Journal|June 2, 2025
Evaluating the Impact of AI-Based Model-Informed Drug Development (MIDD): A Comparative ReviewBingyu Mao, Yue Gao, Christine Xu, et al.
The AAPS Journal|November 18, 2025
Opportunities for AI-based Model-informed Drug Development: A Comparative Analysis of NONMEM and AI-based Models for Population Pharmacokinetic PredictionBingyu Mao, Yue Gao, Christine Xu, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 24, 2022
Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanomaMalidi Ahamadi, Johannes Kast, Po-Wei Chen, et al.
Journal of Pharmaceutical Sciences|April 21, 2012
Prediction of concentration-time profile and its inter-individual variability following the dermal drug absorptionSebastian Polak, Cyrus Ghobadi, Himanshu Mishra, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 19, 2023
Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migrainePo-Wei Chen, Mats O Karlsson, Sebastian Ueckert, et al.
Medrxiv : the Preprint Server for Health Sciences|March 23, 2026
When Survival Improves But Quality of Life Does Not: A Model-Based Meta-Analysis of Immune Checkpoint InhibitorsYimeng Sun, Shiwon Chang, Kayden Tang, et al.
Journal for Immunotherapy of Cancer|May 19, 2017
Evaluation of dosing strategy for pembrolizumab for oncology indicationsTomoko Freshwater, Anna Kondic, Malidi Ahamadi, et al.
Clinical and Translational Science|June 9, 2022
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T-cellular therapy developmentJohannes Kast, Saeideh Nozohouri, Di Zhou, et al.
Pageof 3